CDX2 expression in leukemic and healthy control primary BM and PB samples. Patients presenting with leukemia show significantly higher CDX2 expression than healthy controls. CDX2/PBGD ratio (%) was analyzed for leukemia and healthy donor BM or PB samples. Healthy donors and leukemia patients were grouped according to their CDX2/PBGD ratio (%): low expressers (0 ≤ ratio < 4); low-intermediate expressers (4 ≤ ratio < 8); high-intermediate expressers (8 ≤ ratio < 12); and high expressers (12 ≤ ratio). Numbers represent mean CDX2/PBGD ratio (%) ± SD in each subgroup consisting of n patients. *Significant differences between low expressers from leukemia groups compared with the healthy controls, as determined by Wilcoxon 2-sample, 1-sided test, SAS system, NPAR1WAY procedure. ALL indicates acute lymphoblastic leukemia; c-ALL, common acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; B-CLL, B-cell chronic lymphocytic leukemia; and AML, acute myeloid leukemia.